| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Carcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor | Details |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | Details |
| CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
| DXC-006 | DXC-006; DAC-006 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Hematologic Neoplasms; Lung Neoplasms; Solid tumours | Details |